KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elanco Animal Health (ELAN) Cash & Equivalents (2017 - 2025)

Elanco Animal Health's Cash & Equivalents history spans 9 years, with the latest figure at $545.0 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 16.45% year-over-year to $545.0 million; the TTM value through Dec 2025 reached $545.0 million, up 16.45%, while the annual FY2025 figure was $545.0 million, 16.45% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $545.0 million at Elanco Animal Health, up from $505.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $638.0 million in Q4 2021 and bottomed at $318.0 million in Q1 2023.
  • The 5-year median for Cash & Equivalents is $464.0 million (2022), against an average of $452.0 million.
  • The largest annual shift saw Cash & Equivalents tumbled 58.3% in 2021 before it soared 41.16% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $638.0 million in 2021, then plummeted by 45.92% to $345.0 million in 2022, then grew by 2.03% to $352.0 million in 2023, then skyrocketed by 32.95% to $468.0 million in 2024, then increased by 16.45% to $545.0 million in 2025.
  • Per Business Quant, the three most recent readings for ELAN's Cash & Equivalents are $545.0 million (Q4 2025), $505.0 million (Q3 2025), and $539.0 million (Q2 2025).